ClinicalTrials.gg
CompletedNCT03973840Updated Jul 9, 2019

Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes

A Phase 1 interventional study of Testosterone Undecanoate in Hypogonadism, Male, sponsored by Clarus Therapeutics, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-09.

Sponsored by Clarus Therapeutics, Inc. · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was Jul 2018, 8 years 3 months ago, and no results have been posted to the registry.
  • Registered 10 months after the study started (first participant enrolled Jul 2018, registered Jun 2019).
Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation

Read the detailed description

This was an open-label, non-randomized, single-sequence study in which men dosed with JATENZO had blood drawn into 3 different types of blood-collection tubes (ie, Plain, EDTA, and NaF-EDTA). These tubes were then processed in different ways (ie, different durations between phlebotomy and centrifugation, different holding temperatures [room temperature or on ice] between phlebotomy and centrifugation). After defined periods of incubation, the tubes were centrifuged and the serum/plasma transferred into vials and frozen. The testosterone and TU levels in the serum/plasma were then measured using validated liquid chromatography/tandem mass spectrometry assays.

02

Conditions studied

  • Hypogonadism, Male

Browse trials for

03

In context

Eunuchism

75 studies on the registry are indexed under Eunuchism; 21 are open to participants now.

This study's enrollment of 13 is below the median of 60 across 55 interventional studies indexed under Eunuchism.

Browse Eunuchism studies →

Lead sponsor

Clarus Therapeutics, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects were required to meet all of the following criteria in order to be eligible for the study:

  1. Male (gender at birth) 18 to 65 years of age, inclusive, and legally able to give , as applicable by law. The percentage of non-Hispanic and Hispanic men was specified to be approximately ≥ 70% and ≤ 30%, respectively.
  2. Adequate venous access in the left or right arm to allow collection of a number of blood samples via a venous cannula or needle sticks
  3. Naïve to androgen-replacement therapy
  4. Willing to consume the entire protocol-specified breakfast and dinner meals
  5. Average screening systolic blood pressure \< 140 mmHg and/or diastolic blood pressure \< 90 mmHg
  6. Voluntarily gave written informed consent to participate in this study -

Exclusion criteria

Exclusion Criteria:

Subjects who met any of the following criteria were not eligible for participation in this study:

  1. History of hypertension or taking anti-hypertensive medications
  2. Intercurrent disease deemed , in the opinion of the Investigator, of any type; in particular, liver, kidney, uncontrolled or poorly controlled heart disease, including congestive heart failure, coronary heart disease, heart attack or cerebrovascular accident in prior 6 months, or psychiatric-illness, including severe depression
  3. which Principal Investigator, or designate, believed was clinically significantly abnormal
  4. Intercurrent process or disease which could have impacted the absorption of JATENZO, in particular vomiting, nausea, diarrhea, or inflammatory bowel disease
  5. Current use of the following groups of drugs that affect testosterone levels, testosterone metabolism, or levels of testosterone metabolites, namely antiandrogens, 5 alpha reductase inhibitors (eg, dutasteride, finasteride), estrogens, long-acting opioid analgesics (eg, methadone hydrochloride, buprenorphine hydrochloride), or human growth hormone
  6. History of or was currently being evaluated for breast or prostate cancer
  7. Prostate specific antigen above the
  8. Positive test for antibodies to type 1 or 2, surface antigen, or antibodies to virus at the Screening visit
  9. Positive urine drug test at the Screening visit
  10. Current treatment with oral lipase inhibitors (eg, orlistat [Xenical]), bile acid-binding resins (eg, cholestyramine [Questran], colestipol [Colestid]), fibric acid derivatives (eg, clofibrate [Atromid-X], gemfibrozil [Lopid]), and probucol (Lorelco).
  11. Smokers who were unable to refrain from smoking during the confinement period required in this study
  12. Current evidence of or history of abuse of alcohol or any drug substance within the previous 2 years
  13. Receipt of any drug as part of a research study within 30 days of initial dose administration in this study
  14. Blood donation (usually 550 mL) within the 12-week period before the initial study drug dose
  15. Hematocrit \< 35% or > 50%
  16. ≥ 31 kg/m2 -
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    healthy men treatment arm

    Subjects were given 15 doses over 8 days, and then blood was drawn into several types of collection tubes at different storage conditions.

    Drug: Testosterone Undecanoate

Interventions

06

What researchers measure

Primary outcomes

  1. measure rate of post-collection TU-to-testosterone conversion in 3 types of collection tubes

    To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation

    Time frame: 8 days

Secondary outcomes

  1. rate of post-collection TU-to-testosterone conversion, as manifested by increases in testosterone concentration, in EDTA and NaF-EDTA collection tubes

    To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in EDTA and NaF-EDTA tubes held at room temperature or on ice prior to centrifugation

    Time frame: 8 days

  2. magnitude of overestimation of the true circulating testosterone concentration at 5 hours postdose

    To estimate the magnitude of overestimation of the true circulating testosterone concentration at 5 hours postdose, when blood was collected in various tubes and the tubes were held at room temperature or on ice.

    Time frame: 8 days

  3. healthy men's testosterone levels in serum and plasma

    To compare healthy men's testosterone levels in serum and plasma from Plain and EDTA tubes, respectively

    Time frame: 8 days

Other outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    To characterize the safety and tolerability of JATENZO

    Time frame: 8 days

07

Study locations

1 site
  • Clarus Therapeutics, Inc
    Northbrook, Illinois 60062, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Jul 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2019
First posted
Jun 4, 2019
StartActual
Jul 15, 2018
Primary completionActual
Jul 31, 2018
CompletionActual
Jul 31, 2018
Last update
Jul 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03973840
Lead sponsor
Clarus Therapeutics, Inc.
Collaborators
Celerion; Syneos Health; ARUP Laboratories
Responsible party
Sponsor
First posted
Jun 4, 2019
Start date
Jul 15, 2018
Primary completion
Jul 31, 2018
Completion
Jul 31, 2018
Last update
Jul 9, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Testosterone undecanoate

Start the discussion